Metastatic Breast Cancer Access to Care Act

On March 11, 2025, Representative Garbarino (R-NY) introduced HR 2048, the Metastatic Breast Cancer Access to Care Act. The bill eliminates the 5-month waiting period for Social Security Disability Insurance (SSDI) benefits and the subsequent 24-month waiting period for Medicare coverage for individuals diagnosed with metastatic breast cancer. This patient population currently faces a 29-month cumulative delay before accessing Medicare benefits — the bill condenses that to near-immediate eligibility upon disability determination. The bill has been referred to the House Committee on Ways and Means. An identical companion bill, S3442, was introduced in the Senate and referred to the Committee on Finance. The 225 cosponsors and bipartisan sponsorship signal moderate legislative momentum, but the early-stage committee referral means passage is not imminent. The legislation does not authorize or appropriate any specific dollar amount — it is a regulatory change to eligibility timing. The financial impact flows through to health insurers as an acceleration of premium and service revenue from an estimated ~10,000 to ~20,000 metastatic breast cancer patients per year (based on CDC incidence and disability claim data). For major Medicare Advantage insurers, this means collecting premiums 29 months earlier per patient than under current law. While the absolute revenue impact is modest relative to these companies' multibillion-dollar top lines, the legislative signal is directionally positive for the managed care sector. Structural winners are health insurers with significant Medicare Advantage exposure. UnitedHealth Group ($UNH) and Humana ($HUM) are the purest plays — Humana derives ~85% of premium revenue from Medicare Advantage, and UNH's UnitedHealthcare Medicare business plus Optum care delivery capture both insurance and service revenue from these patients. CVS Health ($CVS) benefits through Aetna Medicare and Caremark PBM. Cigna ($CI), Molina ($MOH), and Centene ($CNC) have smaller but material Medicare exposure. The bill does not increase total healthcare spending — it shifts it forward — so the revenue impact is a timing acceleration rather than a net new pool of funds. Real market data shows a strong sector-wide rally over the past 7 days (April 23-30, 2026). Centene ($CNC) surged +28.5%, Humana ($HUM) +14.2%, Molina ($MOH) +10.2%, CVS ($CVS) +7.0%, UnitedHealth ($UNH) +3.4%, and Cigna ($CI) +3.7%. Over the trailing 30 days, all six tickers have posted double-digit gains ranging from 7.1% (CI) to 64.1% (CNC). This rally predates any material legislative action on HR 2048 (which has been dormant in committee for 13 months), suggesting the move is driven by broader sector catalysts — potentially managed care rate announcements, Medicare Advantage premium updates, or unrelated policy tailwinds. HR 2048 itself is a small positive fundamental signal that adds mild upward pressure, but it is not the primary driver of current price action. The legislative path forward requires passage by the House Ways and Means Committee, a full House vote, Senate Finance Committee consideration, a Senate floor vote, and presidential signature. With identical companion bills introduced in both chambers and 225 bipartisan House cosponsors, the bill has stronger than average early-stage support. However, Congress has not advanced this to a floor vote in the 13 months since introduction. Passage probability in the current Congress is moderate — the bill is likely to be folded into a larger healthcare package (e.g., year-end omnibus or Medicare extenders bill) rather than passing as a standalone.